Abstract: Serum amyloid A (SAA), a classical, acute-phase protein, is produced predominantly by hepatocytes in response to injury, infection, and inflammation. It has been shown that SAA primes leukocytes and induces the expression and release of proinflammatory cytokines. Here, we report that SAA induces NO production by murine peritoneal macrophages. Using specific inhibitors, we showed that NO production was dependent on inducible NO synthase thorough the activation of ERK1/2 and p38 MAPKs. Moreover, SAA activity was decreased after proteolysis but not with polymyxin B, a lipid A antagonist. Finally, we found that NO production was dependent on functional TLR4, a receptor complex associated with innate immunity. Macrophages from C3H/HeJ and C57BL/10ScCr mice lacking a functional TLR4 did not respond to SAA stimulation. In conclusion, our study makes a novel observation that SAA might be an endogenous agonist for the TLR4 complex on macrophages. The contribution of this finding in amplifying innate immunity during the inflammatory process is discussed. J. Leukoc. Biol. 83: 000 -000; 2008.
INTRODUCTION
Infection, trauma, inflammation, stress, and other injuries can provoke an archetypical range of physiological changes, collectively known as acute-phase response. Part of this response consists of an increased production and release of specific acute-phase proteins such as serum amyloid A (SAA), C-reactive protein, mannose-binding protein, and others [1] . The production of SAA as well as other acutephase proteins is usually triggered by inflammatory cytokines such as IL-6, IL-1, and TNF-␣. These cytokines are produced mainly by activated macrophages and monocytes but also by endothelial cells, lymphocytes, and other cells [2] . SAA appears to have a broad range of biological activities that includes immunomodulation, tissue remodeling [3] , and immunosurveillance [2] . We have characterized the immunomodulatory properties of SAA in neutrophils by showing that SAA induces the expression and release of inflammatory cytokines and enhanced response to opsonized particles [4 -7] . Others have shown that SAA mobilizes intracellular calcium and stimulates cyclooxygenase-2 expression and PGE 2 synthesis [8 -10] .
A plethora of reports in recent years has shown that a number of endogenous molecules might also be potent activators of TLRs (reviewed in ref. [11] ). For instance, Ohashi et al. [12] , using macrophages from C3H/HeJ mice with point mutation in the Tlr4 gene, demonstrated that macrophage stimulation by recombinant human heat shock protein 60 (rhHsp60) required functional TLR4.
In the present study, we determined whether SAA is capable of activating TLR4. For this, we monitored the production of NO by peritoneal macrophages stimulated with SAA in TLR4-sufficent and TLR4-deficient mice strains. As TLR4 signaling includes the adaptor molecule MyD88 and activation of MAPKs, we also investigated whether MyD88 deficiency or inhibition of specific MAPKs influences NO production induced by SAA.
Here, we show that macrophage activation by SAA is TLR4-dependent. The downstream pathways involved in SAA-induced NO production include ERK1/2 and p38 activation but not the MyD88 pathway. We suggest that SAA might be an endogenous TLR4 agonist.
MATERIALS AND METHODS

Reagents
PeproTech Inc. (Rocky Hill, NJ, USA) supplied the rhSAA. According to the supplier, the amount of endotoxin contaminant is lower than 0.1 ng/1 g protein, and purity is greater than 98%, as assessed by SDS-PAGE gel and HPLC analyses. Con A, RPMI 1640, and streptomycin were purchased from Sigma Chemical Co. (St. Louis, MO, USA). Calbiochem Novabiochem Corp. (San Diego, CA, USA) supplied polymixyn B, PD98059, and SB203580. Proteinase K was purchased from Invitrogen (San Diego, CA, USA). R&D Systems (Minneapolis, MN, USA) supplied the anti-mouse TNF-␣ antibody.
Animals
Female C57BL/6, C3H/HePas, C3H/HeJ, C57BL/10ScCr, and MYD88 Ϫ/Ϫ [knockout (KO)], 4-to 8-week-old mice under standard pathogen-free conditions, were bred in the breeding unit of the Institute of Biomedical Sciences (São Paulo, Brazil). The Faculty of Pharmaceutical Sciences, University of São Paulo Ethical Committee (Brazil), approved all experiments.
Administration of Con A
When indicated, the animals were injected i.p. with 10 g Con A (Con A-primed macrophages) or sterile saline (resident macrophages) and were killed 48 h after treatment.
Cells and cell culture
Macrophages were obtained from mice by washing their peritoneal cavities with 5 ml ice-cold PBS. The cells from individual mice were centrifuged (160 g, 10 min, 4°C), ressuspended in complete RPMI-1640 medium, and adjusted to 2.0 ϫ 10 6 cells/ml. Total and differential cell counts were performed on fixed and stained cell suspensions with 0.05% crystal violet dissolved in 3% acetic acid (final solution). Cell suspensions used in all experiments consisted of at least 85% macrophages, as judged by morphological criteria. For culturing, 100 l cell suspension was plated into each well of 96-well, flat-bottom, tissue-culture plates (Corning, Corning, NY, USA), and cultures were incubated at 37°C and 5% CO 2 .
NO production
NO production was quantified by measuring the accumulation of the stable, oxidative metabolite, nitrite (NO 2 -) in culture supernatants by the standard Griess reaction as described previously [13] . All determinations were performed in duplicate and expressed as micromoles concentration of NO.
Inhibitors of MAPK
The experiments with MAPK include the use of 10 M SB203580 (a p38 MAPK inhibitor) or 50 M PD98059 (a MAPK ERK, MEK-1). These inhibitors were preincubated with macrophages for 15 min before the administration of SAA and then cultured for 24 h.
Inducible NO synthase (iNOS) expression
iNOS expression was measured by Western blot analysis of total cell lysates. Briefly, cells were lysed in buffer containing 20 mM Hepes, 150 mM NaCl, 1.5 mM MgCl 2 , 1 mM EGTA, 10% glycerol, 1% Triton X-100, aprotinin (1 g/mL), leupeptin (1 g/mL), and 1 mM PMSF, pH 7.5, containing phosphatase inhibitors. Total cell lysates (20 g/lane) were resolved in 8% SDSpolyacrylamide gel and blotted onto nitrocellulose sheets. Blots were probed using polyclonal antibody against iNOS (BD Transduction Laboratories, BD Biosciences, San Jose, CA, USA), diluted at 1:1000. After incubation with an appropriate HRP-conjugated secondary antibody, blots were developed using the Pierce system.
Measurement of endotoxin activity
The endotoxin activities of rhSAA and LPS from Escherichia coli 0111:B4 (Sigma-Aldrich, St. Louis, MO, USA) were determined using the Limulus amebocyte lysate (LAL) assay kit (BioWhittaker, Walkersville, MD, USA), which was performed according to the manufacturer's recommendations. We found that 10 g/mL rhSAA preparation contained 3.6 endotoxin units (EU)/ mL, whereas 1 ng/mL LPS contained 5 EU/mL.
Removal of endotoxin from rhSAA
To remove residual endotoxin of rhSAA, we submitted our preparation to the Triton X-114 method as described by Aida and Pabst [14] . The rhSAA was diluted in free endotoxin water (1 mg/mL), and the solution was submitted to two to three cycles of Triton X-114 extractions. After each cycle, the rhSAA content was determined by SDS-PAGE (18%). We found that after three cycles, the protein yield was very poor (we lost more than 60% of the protein) and that the endotoxin level of rhSAA was similar to the original preparation. We emphasized that we succeeded to remove endotoxin from other LPScontaminated protein, such as commercial OVA, rhHsp60, or rhIDO (data not shown). Therefore, we used original rhSAA preparation throughout the experiments.
Proteinase K digestion and polymyxin B treatment
To exclude the effect of possible endotoxin contaminants, proteinase K (50 g/mL) or polymyxin B (25 g/mL) was added to SAA (10 g/mL) for 45 min at 37°C in PBS (containing Ca ϩϩ and Mg ϩϩ ). The samples were then added to macrophage cultures, and 48 h later, the nitrite concentrations were determined.
Statistical analysis
The statistical analysis consisted of the one-way ANOVA with the StudentNewman-Keuls multiple comparisons test.
RESULTS
SAA induces NO production by resident and Con A-primed macrophages
We first determined whether SAA activates resident peritoneal macrophages for the production of NO. As shown in Figure  1A , SAA induced the production of NO in a dose-dependent manner. NO production was below detection at a concentration of SAA lower than 0.5 g/mL (data not shown). Next, we evaluated the NO production 24 and 48 h after SAA stimulation (Fig. 1B) . At 48 h, although the production of NO was higher than that obtained in 24 h of macrophage cultures, it was not statistically significant. Finally, we determined the production of NO by Con A-primed macrophages. We have previously shown that i.p. injection of Con A, a polyclonal T cell activator, enhances various macrophage functions [15] [16] [17] . Thus, to verify whether Con A-primed macrophages were more responsive to SAA, we collected macrophages from mice injected with 10 g Con A. It was found that the production of NO by Con A-primed macrophages was higher than that obtained with resident macrophages (Fig. 1C) .
We conclude that SAA is a potent inducer of NO and that NO production augments in Con A-primed macrophages.
Involvement of MAPKs but not TNF-␣ in NO production
We have previously shown that SAA induces the expression and production of TNF-␣ in human neutrophils [6] . Given the fact that TNF-␣ is involved in NO production (reviewed in ref.
[18]), we evaluated whether the addition of anti-TNF-␣ antibodies could affect NO production. As shown in Figure 2A , treatment of macrophage cultures with anti-TNF-␣ antibody did not inhibit NO production. Next, we examined the involvement of MAPKs in NO production, as MAPKs are involved in TNF-␣ production [6] and other inflammatory mediators [19, 20] . We used two highly selective p38 and ERK1/2 inhibitors (SB203580 or PD98059, respectively) to treat macrophages.
After 15 min of incubation, macrophage cultures were exposed to SAA for 24 h, and the NO production and iNOS expression were determined. Before performing these experiments, we determined cell viability after incubation with 10 M SB203580 or 50 M PD98059. We found that at these concentrations, the imidazole inhibitors were not cytotoxic, as assessed by the trypan blue exclusion test (data not shown). Figure 2 , B and C, shows that both inhibitors caused a significant decrease in SAA-induced NO production and iNOS expression, with SB being more effective.
Functional TLR4 is required for NO production induced by SAA Acute-phase proteins are endogenous molecules that ultimately amplify innate immune responses. Although most of them are involved in opsonization and blood clotting, SAA appears to be involved in leukocyte activation and as such, resemble the activities evoked by LPS (cytokine production and NO generation). Therefore, we investigated whether SAA might be an endogenous TLR agonist. To test this hypothesis, we used two mouse strains, C3H/HeJ (HeJ) and C57BL/10ScCr (Cr), with defects in the gene encoding the TLR4 complex that results in unresponsiveness to LPS [21] . As shown Figure 3 , A and B, macrophages from TLR4-deficient strains did not produce significant amounts of NO upon SAA stimulation. In contrast, NO production induced by SAA was robust in C3H/ HePas or B6 TLR4-sufficient mice. In addition, we investigated whether MyD88, an adaptor molecule of TLR4 signaling, was involved in the production of NO. We found that NO production by macrophages from MyD88-deficient mice was similar to wild-type (B6) macrophages (Fig. 3C) . In summary, our data indicate that functional TLR4 but not MyD88 molecule is required for SAA-induced NO production.
Endotoxin contamination does not reproduce SAA-induced NO production
Having this drawback and to rule out the possible LPS effect, we compared the NO production induced by SAA at concentrations of 10 and 1 g/mL with those obtained with increasing concentrations of LPS with EU/mL ranging from 0.5 to 50, as determined by LAL. As shown in Figure 4 , SAA at doses of 10 or 1 g, which contained, respectively, 3.6 and 0.36 EU/mL, induced a significant NO production. In contrast, LPS, exhibiting similar EU/ml, did not trigger a significant NO production (Fig. 4) . LPS only induced a significant NO release when 50 EU/mL LPS was added to the cultures. However, the levels of NO produced at this dose of LPS were about one-third of that obtained with 10 g/mL SAA (Fig. 4) . Another possibility was that SAA and LPS act in a synergistic way. To test this hypothesis, we added LPS at increasing concentration to 1 g/mL SAA. As shown in Figure 4 , addition of LPS up to 50 EU/mL did not enhance NO production, ruling out, therefore, the possible synergistic effect of LPS on SAA activity.
Proteinase K but not polymyxin B impairs SAA-induced NO production
Finally, we tested whether polymyxin B or proteinase K treatment would affect rhSAA activity. Polymyxin B is a cationic cyclic lipopeptide that binds stoichiometrically to the lipid A moiety of LPS and blocks its biological effects, whereas proteinase K is a serine protease that cleaves peptide bonds at the carboxylic sides of amino acids [22, 23] . We found that polymyxin B added to SAA did not affect NO production, and its addition to LPS totally abrogated the NO production (Fig. 5, A  and B) . Conversely, proteinase K treatment inhibited NO production by SAA but not by LPS (Fig. 5, C and D) . Although indirectly, these results suggest that rhSAA but not LPS is responsible for NO production.
DISCUSSION
This study makes the novel observation that SAA induces NO production by macrophages via TLR4 and suggests that SAA acts as an endogenous TLR4 ligand. This assumption was based on experiments performed in TLR4-deficient strains. Indeed, studies with TLR4 mutant mice, C3H/HeJ or C57BL/ 10ScCr, were valuable tools to identify many endogenous TLR4 ligands such as fibrinogen, heparan sulfate, hyaluronic acid, and fibronectin extra domain A (reviewed in ref. [24] ). Seong and Matzinger [25] have hypothesized that endogenous TLR4 ligands are characterized by the exposure of hydrophobic portions that would act as a universal damage-associated molecular pattern to initiate repair, remodeling, and immunity. Indeed, SAA contains hydrophobic amino acid-rich regions that associate with lipoprotein and other ligands [26] . It re- mains to be determined whether these hydrophobic regions are critical for TLR4 signaling by SAA.
The production of NO in response to SAA by macrophages from TLR4-suficient mice was dose-dependent. As purified, endogenous TLR4 agonists are usually obtained from recombinant bacteria, a major concern in relation to our results is whether the recombinant SAA was contaminated with endotoxin. Thus, we first determined the endotoxin activity present in SAA and found that 10 g SAA contained 3.6 EU/mL, which is near 1 ng LPS. Then, we submitted our rhSAA preparation to the Triton X-114-phase separation method, but we could not remove LPS from our SAA preparation. This was not the case when we used other LPScontaminated proteins. The low recovery obtained with rhSAA and the difficulty in purifying SAA by Triton X-114 treatment are probably a result of the fact that rhSAA has hydrophobic sites and low molecular weight. Thus, to rule out the possibility that NO production is a result of LPS contamination, we used two experimental approaches that have been used by other authors when the SAA preparation is not LPS-free [27] [28] [29] . First, we added LPS at a different concentration starting with a similar concentration that we detected in our SAA preparation and increasing the concentration to ten-to 100-fold. We found 5 EU/mL LPS, which is equivalent to 1 ng, induced negligible production of NO by resident macrophages. Significant production of NO was only observed with a tenfold-higher dose, and the amount of NO produced was roughly threefold lower than that induced by SAA. Even with concentrations of LPS 100-fold higher, the NO production was still lower than that obtained with SAA (data not shown). We also ruled out a possible synergism between SAA and LPS, as addition of LPS at different doses to 1 g SAA did not enhance NO production. Second, pretreatment of SAA solution with polymyxin B did not interfere in NO production. In contrast, pretreatment of SAA with proteinase K decreased SAAinduced NO production significantly.
We also found that SAA stimulated the production of TNF-␣ [6] , which subsequently could induce NO. However, we excluded the participation of TNF-␣ in mediating NO production, as neutralizing antibodies against TNF did not inhibit SAA-induced NO release. The induction of iNOS expression and NO production by SAA was dependent on p38 and ERK1/2 pathways, as specific MAPK inhibitors SB203580 and PD98059 inhibited iNOS expression and NO production. This finding is in agreement with the recognized signaling pathway for iNOS expression promoted in macrophages by other stimuli [19, 20] and in other cell types [30] . Moreover, priming of macrophages by in vivo injection of a plant lectin Con A resulted in an enhanced production of NO after stimulation in vitro with SAA. Con A is a polyclonal T cell activator and mimics an IFN-␥-dependent macrophage activation as previously reported [15] [16] [17] (reviewed in ref. [31] ). Thus, it is likely that enhanced NO production resulted from a synergy between IFN-␥ signaling and SAA signaling through the TLR4 molecule.
Results obtained in MyD88-deficient mice indicate that this pathway is dispensable for SAA-induced NO production. Thus, it is likely that the Toll/IL-1R domain-containing, adaptorinducing IFN-␥ pathway might be responsible for NO production [32] . Although a functional TLR4 is required for NO production, we do not know whether additional receptors are involved in optimal TLR4 signaling. It is known that SAA interacts with at least four distinct receptors: formyl peptide-receptor like-1, found in neutrophils [33] ; Tanis, expressed on the hepatic tissue [34] ; CD36 and lysosomal integral membrane protein-II analogous-1, a scavenger of high-density lipoprotein, found in various types of cells [35] ; and receptor for advanced glycation end-products, a multiligand receptor [28] . Whether these receptors are essential or dispensable for optimal TLR4 signaling remains to be determined, but they could act like the CD14 molecule in the activation of TLR4 [36] . It is also important to determine whether SAA itself binds to the TLR4 receptor or is a carrier of other substances that activate the receptor. Another possibility is that SAA binds to LPS, and the complex SAA/LPS decreases the threshold of pathogen-associated molecular pattern detection, which in turn, enhances TLR4 signaling. This was demonstrated recently to occur with Hsp60, a putative, endogenous TLR4 ligand [37] .
SAA, like other acute-phase proteins, is thought to play a role in innate defense by binding Gram-negative bacteria and acting as an opsonin [38] . However, it is becoming clear that SAA fulfills other immunological functions more related with cellular immunology that include its ability to associate with leukocytes, to induce the release of cytokines [4 -6, 27, 39] , to prime leukocytes for the release of reactive oxygen species [7] , and to inhibit apoptosis [29] . Our finding that SAA triggers NO release adds a new, immunological function to this protein. Most of the biological effects mediated by SAA, such as augmentation of microbicidal activity [9] and angiogenesis [40] , could be partly mediated by NO.
In conclusion, the activities of SAA are far from being restricted to opsonin-like activity, as our work indicates SAA could be a key element in the progression and/or resolution of the inflammatory process triggered by infection or injury.
